Core Insights - BioTissue Holdings, Inc. has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, Inc., allowing BioTissue to focus on ocular market leadership and innovation in eye care solutions [1][2][3] Company Overview - BioTissue specializes in utilizing human birth tissue for regenerative healing, particularly in treating acute and chronic ocular surface conditions [4] - The company has developed a portfolio of cryopreserved amniotic membrane products using proprietary CryoTek® technology, which preserves the tissue's structural and functional integrity [4] - BioTissue has conducted over 1 million human procedures with its products and has over 420 peer-reviewed publications supporting its technology [4] Strategic Focus - Following the divestiture, BioTissue will concentrate on advancing interventional therapies for ocular conditions, including products like Prokera, CAM360 AmnioGraft, and AmnioGuard [2][3] - The company aims to prioritize product innovation, professional education, and comprehensive customer support within the eye care market [2] Partnership with BioStem - BioStem Technologies will acquire exclusive rights to BioTissue's Neox and Clarix product lines, integrating BioTissue's surgical sales team into its commercial organization [2][3] - BioStem's CEO highlighted the complementary strengths of BioTissue's portfolio to their existing business, indicating a strong potential for growth and improved patient outcomes [3]

Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercializatio ...

Group 1 - Atresmedia Corporación de Medios de Comunicación experienced a significant increase in short interest, rising by 116.4% from 640 shares on November 30th to 1,385 shares by December 15th [2] - The average daily trading volume is 2,052 shares, resulting in a days-to-cover ratio of 0.7 days [2] - The stock opened at $5.60, with a fifty-day moving average of $6.09 and a 200-day moving average of $6.13 [3] Group 2 - Atresmedia is a leading Spanish multimedia group that operates a diverse portfolio of free-to-air television channels, including flagship networks Antena 3 and laSexta [4] - The company also manages thematic channels such as Neox, Nova, Mega, and Atreseries, catering to various audience segments with a range of content [4] - In addition to television, Atresmedia operates a network of radio stations, including Onda Cero, Europa FM, and Melodía FM [5]